An error appeared in the 1 January 2011 issue of the journal [Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens. Clin Infect Dis 2011; 52(1):31–40. https://doi.org/10.1093/cid/ciq031]. In line 6 of column 2 of Table 5, the current number of microbiologically evaluable patients with monomicrobial Staphylococcus aureus treated with telavancin is reported as 85. The correct number should be 89 due to miscounting multiple samples with the same organism. Table 5 column 2 line 6, “Telavancin, % (proportion) of patients: Monomicrobial S. aureus – Vancomycin MIC ≥1 µg/mL” should read “83.1 (74/89).”

中文翻译：

---

勘误表

2011年1月1日的期刊[Rubinstein E，Lalani T，Corey GR，et al。特拉万星与万古霉素治疗因革兰氏阳性病原体引起的医院获得性肺炎。Clin Infect Dis 2011；52（1）：31–40。https://doi.org/ 10.1093 / cid / ciq031 ]。在表5第2栏的第6行中，据报道，使用特拉万星治疗的具有微生物学评估的单药金黄色葡萄球菌患者的数量为85。由于对同一个生物体的多个样品进行了错误计数，正确的数量应为89。表5第2栏第6行，“替拉万星，患者的百分比（比例）：金黄色葡萄球菌-万古霉素MIC≥1 µg / mL”应改为“ 83.1（74/89）”。